RxPack becomes Associate Member of IPAC-RS

8th, June 2022

Oggiono (LC) Italy, June 6th, 2022, RxPack (IT03946630138), a global developer and manufacturer of Pharmaceutical Dispensing Solutions and a leading player in pMDIs & nasal sprays announces that it has become an Associate Member of IPAC-RS, the International Pharmaceutical Aerosol Consortium on Regulation & Science.


Massimo Carrara, CEO RxPack, stated about the announcement: “RxPack is growing its leadership and recognition in the world of pMDIs. Associate membership in  IPAC-RS is timely and will facilitate  our exposure of key trends and engagement on relevant global development and regulatory matters”.


Alberto Colombo, RxPack Head of R&D added: “Being part of IPAC-RS is a great opportunity for us to share cross-industry knowledge that allows us to better support our pharmaceutical partners.  Engaging in IPAC-RS will assist us as we maintain a dedicated focus on patients in this time of transition to green propellants for pMDI products”.


Specialized in the development and manufacture of pMDIs and medical devices for the Pharmaceutical and Generics Industries, RxPack brings a wealth of expertise, know-how and state-of-the-art technology thanks to a 60-year experience in the Aerosol & Spray Delivery platforms.

A 50:50 JV between Coster and Lindal, RxPack is the result of the vision and long-term focus of two family-owned companies.

Coster Group: a leading multinational provider of spray packaging solutions and filling machines, owned by the Segatta Family.

Lindal Group: a leading multinational company specializing in the design, manufacture and supply of aerosol dispensing packaging solutions, owned by the Lilienthal Family.


IPAC-RS, the International Pharmaceutical Aerosol Consortium on Regulation & Science, has been the leading voice of OINDP (orally inhaled and nasal drug products) for over 20 years. Through joint research and multiple activities, IPAC-RS has developed best practices, contributed to advances in science-based regulatory approaches, ensuring the availability, safety, efficacy and quality OINDP. IPAC-RS works collaboratively across the industry and with external experts from regulatory agencies, standard-setting bodies, academia, pharmacopeias, healthcare providers and patient groups. IPAC-RS shares its findings through publications, online tutorials, in-person training courses, webinars, and conferences.